Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EBT (2016 - 2025)

Dexcom (DXCM) has disclosed EBT for 16 consecutive years, with $340.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 61.24% to $340.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 53.51% increase, with the full-year FY2025 number at $1.1 billion, up 53.51% from a year prior.
  • EBT was $340.7 million for Q4 2025 at Dexcom, down from $352.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $352.3 million in Q3 2025 to a low of $36.1 million in Q1 2022.
  • A 5-year average of $160.9 million and a median of $150.2 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 55.77% in 2021, then surged 111.55% in 2023.
  • Dexcom's EBT stood at $68.2 million in 2021, then skyrocketed by 95.31% to $133.2 million in 2022, then skyrocketed by 84.83% to $246.2 million in 2023, then fell by 14.18% to $211.3 million in 2024, then surged by 61.24% to $340.7 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EBT are $340.7 million (Q4 2025), $352.3 million (Q3 2025), and $241.1 million (Q2 2025).